USPTO Allows Patent for Artelo's Lead Drug Formulation, Extending Protection to 2041
ARTL is trading near its 52-week low of $0.705 (9.2% above the low).
Summary
Artelo received a Notice of Allowance from the USPTO for a patent covering the intended commercial formulation of ART27.13, its lead drug in two Phase 2 studies. The allowed claims protect compositions dispersed in polyethylene glycol, extending patent protection through 2041. This strengthens the IP moat around a program that has shown promising interim Phase 2 data in cancer-related anorexia, with all high-dose patients gaining weight versus placebo. The company faces going concern doubts and heavy dilution from recent ATM offerings, so this patent milestone is a rare positive catalyst. DREAM study results for glaucoma are expected in Q4 2026.
At the time of this announcement, ARTL was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.71 to $31.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.